Research Briefing | Sep 16, 2021

US | Recovery Tracker sees strong end to summer

US Recovery Tracker sees strong end to summer - iPad

The US Recovery Tracker exited the summer on a bright note. It rose 0.7ppts to 96.7 during the two weeks ended September 3 – the highest reading since late July. Despite downside risks from the Delta variant, the health situation is stabilizing, mobility is nearing its pre-pandemic level, and household spending is steady.

What you will learn:

  • Record equity valuations continue to underpin looser financial conditions, but Covid-related supply constraints are limiting production. Employment took a breather on weaker small business payrolls and increased UI benefits searches.
  • Regional recoveries stabilized in early September. The South posted its first gain since early July as Delta variant infections fell from their peak.
  • New Covid cases remain elevated, but hospitalizations are declining and inoculations are steady at 900k/day. We expect the wider adoption of vaccine mandates following full FDA approval of the Pfizer vaccine will support increasing uptake. 

Tags: CoronavirusEmploymentMacroNorth AmericaRecoveryRecovery TrackerUnited StatesUS economyVaccines
Back to Resource Hub

Related Services

Takaichi’s big win doesn’t affect the fiscal outlook for Japan

Takaichi’s big win doesn’t affect the fiscal outlook for Japan

The ruling Liberal Democratic Party's (LDP) landslide election victory on Sunday doesn't change our expectation of a primary fiscal deficit of 2%-3% of GDP in FY2026-FY2028 – we still see the deficit only starting to decline from FY2029. We also keep our view that the 10-year Japanese government bond (JGB) yield will be at 2.3% at end-2026 and 2.5% at end-2027 and beyond.
US and Chinese strength won’t boost all other economies

US and Chinese strength won’t boost all other economies

Upward revisions to US and Chinese GDP growth in Q4 meant that the previously anticipated soft end to 2025 failed to materialise.